THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 29, 2008--Amgen (NASDAQ:AMGN) will webcast its investor meeting at the upcoming American Society of Clinical Oncology (ASCO) Conference on Sunday, June 1 at 8 p.m. Central Time. Members of Amgen's scientific and management team will participate at the meeting. The company plans to highlight key compounds in its pipeline, including denosumab.
Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors. Information regarding presentation time, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar.
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Cory Rivera, 805-447-1060 (investors)